

Therefore, applicants herein elect with traverse claims 5 and 7, wherein the matrix components are homopolymers of N-vinylpyrrolidone (polyvinylpyrrolidone).

Polyvinylpyrrolidone is used in examples 1 and 2 on pages 10-11 of the specification.

Argument:

Applicants herein distinctly and specifically point out errors in the restriction requirement as required by MPEP § 818.03(c). Applicants repeat below the argument made in the reply to restriction requirement filed on May 8, 2001.

The present invention relates to a pharmaceutical composition which comprises both at least one multiparticulate phase and a matrix phase. An essential feature is a matrix phase which is obtainable by a melt-extrusion process. All the matrix components of claims 5 and 7 are used to form a suitable matrix for the pharmaceutical composition. Therefore, the matrix components relate to a single invention.

Applicants believe that since the applicants made a *bona fide* attempt to advance the application to final action, and the reply of May 8, 2001 was substantially a complete reply to the non-final Office action, but consideration of some matter or compliance with some requirement was inadvertently omitted, applicants should be given a new time period for reply under § 1.134 to supply the omission. 37 CFR 1.134.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit

ROSENBERG et al., Serial No. 09/037,792

any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF



Herbert B. Keil
Reg. No. 18,967

1101 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100

HBK/DSK/kas